AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05694650 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview
Description: Participants can meet with an interviewer alone. The interview should take about 1 hour and will be held in person at MD Anderson, by telephone, or online using a video conferencing app called Zoom
Study NCT06082037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil
Description: Tablet, Oral
Study NCT06082037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Depends on pharmaceutical presentation, Oral
Study NCT05567211 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Free use of the virtual platform.
Description: Access to the virtual platform + general healthy eating and physical activity recommendations. The platform will allow the registration of all the evolution, monitoring of nutritional and sports patterns (with activity bracelet), as well as oxidative stress, hydration, menstrual phase and mood.
Study NCT05567211 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personalized nutritional planning based on the Mediterranean diet + physical exercise + use of mobile application.
Description: Access to the virtual platform + nutritional planning based on the Mediterranean diet + physical activity. The platform will allow the registration of all the evolution, monitoring of nutritional and sports patterns (with activity bracelet), as well as oxidative stress, hydration, menstrual phase and mood.
Study NCT06082037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azithromycin
Description: Depends on pharmaceutical presentation, Oral
Study NCT06082037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, Oral
Study NCT06126913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Antiretroviral Therapy
Description: Newly diagnosed individuals (diagnosed in the prior 6 months) at intervention sites will be offered community ART delivery on a rolling basis during the enrollment window, initiating individuals into groups as close to their date of diagnosis as possible. Newly enrolled individuals will join existing community ART delivery groups, or when a new group is needed based on group size or geographic location, a new group will be formed.
Study NCT05770830 — intervention group
Intervention type: DEVICE
Intervention: Esophageal temperature
Description: Temperature data measured by esophageal temperature probe (disposable probe, Ace-medical, Seoul, Korea)
Study NCT05770830 — intervention group
Intervention type: DEVICE
Intervention: Skin core temperature
Description: Temperature data measured by skin core temperature device measured by 3M™ Bair Hugger™
Study NCT06290102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-56248
Description: Pharmaceutical form: Dry powder~Route of administration: Oral inhalation
Study NCT06290102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fp MDPI
Description: Pharmaceutical form: Dry powder~Route of administration: Oral inhalation
Study NCT05567211 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personalized nutritional planning with an extra intake of berries + physical exercise + use of mobile application.
Description: Access to the virtual platform + nutritional planning with an extra supply of antioxidants using red berries + physical activity. The platform will allow the registration of all the evolution, monitoring of nutritional and sports patterns (with activity bracelet), as well as oxidative stress, hydration, menstrual phase and mood.
Study NCT05106933 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plain water
Description: Measure gastric residual volume during upper endoscopic, after given plain water and carborie 2 hours prior upper endoscopy
Study NCT05106933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carborie
Description: carbohydrate drink
Study NCT05004428 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Retrospective population-based study utilizing administrative data without any intervention.
Study NCT05123599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: JNJ-73763989 injection will be administered subcutaneously.
Study NCT05123599 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-64300535
Description: JNJ-64300535 deoxyribonucleic acid (DNA) vaccine injection will be administered intramuscularly.
Study NCT05123599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETV monohydrate
Description: ETV monohydrate film-coated tablets will be administered orally.
Study NCT05123599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil
Description: Tenofovir disoproxil film-coated tablets will be administered orally.
Study NCT05123599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: TAF film-coated tablets will be administered orally.
Study NCT06518161 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Voluntary
Description: Subjects undergoing scheduled surgery in the operating room at Nantes University Hospital, requiring general anesthesia with placement of an endotracheal intubation tube for invasive mechanical ventilation.
Study NCT05099172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2927088_formulation A
Description: Oral administration
Study NCT05099172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2927088_formulation B_1
Description: Oral administration
Study NCT05099172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2927088_formulation B_2
Description: Oral administration
Study NCT05300971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat therapy
Description: 36 sessions (\~3x per week for 12 weeks) of hot water immersion in 40°C water, sufficient to raise body core temperature to 38.5°C, and 12 weeks of follow-up.
Study NCT05300971 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Thermoneutral water immersion
Description: 36 sessions (\~3x per week for 12 weeks) of thermoneutral water immersion in 36°C water to prevent changes in body core temperature >0.2°C, and 12 weeks of follow-up.
Study NCT05127304 — intervention group
Intervention type: DEVICE
Intervention: Trelegy Ellipta
Description: Trelegy Ellipta with Furoate/Umeclidinium/Vilanterol
Study NCT05127304 — intervention group
Intervention type: DEVICE
Intervention: Stiolto Respimat
Description: Stiolto Respimat with Tiotropium Bromide/Olodaterol
Study NCT05127304 — intervention group
Intervention type: DRUG
Intervention: Furoate/Umeclidinium/Vilanterol
Description: Furoate/Umeclidinium/Vilanterol
Study NCT05127304 — intervention group
Intervention type: DRUG
Intervention: Tiotropium Bromide/Olodaterol
Description: Tiotropium Bromide/Olodaterol
Study NCT04988906 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zoll Accuvent Ventilation Monitor
Description: Provides real-time ventilation quality monitoring (rate and volume)
Study NCT06392113 — intervention group
Intervention type: BEHAVIORAL
Intervention: ACTION FALLS
Description: Falls prevention advice including booklet and videos
Study NCT06440408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Ferumoxytol will be used as a contrast agent for the cMRI
Study NCT00429923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluprednate
Study NCT00429923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05126901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Maltol
Description: Ferric maltol oral suspension: 150 ml amber glass bottle with graduated syringe and adaptor. Oral suspension containing 30 mg elemental iron, in the form of 231.5 mg ferric maltol, in 5 ml suspension~Study dosage: The dose of ferric maltol oral suspension that will be administered for children aged 1 month to \< 2 yrs: 0.1 ml/kg BID, 2 to - 11 yrs: 2.5 ml BID, 12-17 yrs: 5 ml BID.
Study NCT05126901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate
Description: Ferrous sulfate 125 mg/ml (25 mg/ml elemental iron) oral liquid : 15 ml glass bottle.~Study dosage: For ferrous sulfate oral liquid, the dose administered will be for children and adolescents aged 2 years to 17 yrs: 6 mg/kg to the maximum of 4 ml BID.
Study NCT04286282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Pyschotherapy
Description: Group psychotherapy
Study NCT04286282 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Depression Standard of Care
Description: Standard clinical care for depression, which may include the use of selective serotonin re-uptake inhibitors (SSRIs).
Study NCT04286282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Depression Standard of Care
Description: Standard clinical care for depression, which may include the use of selective serotonin re-uptake inhibitors (SSRIs).
Study NCT04286282 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HIV Standard of Care
Description: Standard clinical care for HIV
Study NCT04286282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV Standard of Care
Description: Standard clinical care for HIV
Study NCT05201963 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus Anterior Plane Block
Description: Full aseptic precautions applied. Ultrasound probe will be placed on the patient's midaxillary line in the longitudinal plane (lateral position with arm abduction), at the level of 5th rib, the indicator oriented toward the operator's left. With the rib, pleural line, overlying serratus anterior and latissimus dorsi muscles visualized, then, a 38-mm 22-gauge regional block needle will be advanced in-plane at an angle of approximately 45 degrees towards the 5th rib. After aspiration to avoid intravascular injection 30ml of levobupivacaine 0.25% will be injected anteriorly to the rib and deep to the serratus anterior muscle. The entirety of the needle should be visualized at all times throughout the procedure.6-13-MHz, linear transducer set for small parts and a depth of 1-4 cm is used for this block(15-16).
Study NCT05201963 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: Full aseptic precautions applied. Ultrasound probe will be placed on the back in a transverse orientation to identify the tip of the T5 transverse process. The tip of the transverse process will be centered on the ultrasound screen and the probe will then be rotated into a longitudinal orientation to produce a parasagittal view, in which skin, subcutaneous tissue, trapezius and erector spinae muscle will be visible superficial to T5 transverse process. Echogenic block needle will be inserted in- plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle will be confirmed by injecting 0.5-1 ml normal saline . After aspiration to avoid intravascular injection 30 ml levobupivacaine 0.25% will be performed. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm will be used
Study NCT05400265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX26
Description: Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody
Study NCT05400265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: Humanized Anti-Programmed Death-1 Monoclonal Antibody
Study NCT04906577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: photography+odour
Description: Daily from D0 to D5: a square of cotton cloth will be placed against the child's scalp by the childcare worker in charge of the child, then removed and placed in a sealed box containing a photograph of the child, which will then be given to the mother.
Study NCT04906577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: photography
Description: A neutral smelling cloth will be placed with the child's photograph which will then be given to the mother.
Study NCT05421663 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-90014496
Description: JNJ-90014496, an autologous bi-specific chimeric antigen receptor (CAR) - T cell therapy targeting Cluster of differentiation (CD)19 and CD20.
Study NCT06572748 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 10-week programme
Description: 1. 2-week health education (4 sessions, 60 minutes per session) Social workers and occupational therapists will explain the cognitive training elements of the program and introduce the DementiAbility Methods to the participants. Nutritionist, speech therapists, and Chinese medicine practitioner will share insights from their perspectives to enhance participants' understanding of cognitive impairments.~2. 8-week cooking class (5 sessions, 120 minutes per session) The culinary instructor will teach participants to cook homemade dishes while integrating procedural memory into recipes. Older adults and their caregivers will cook together based on the procedural recipe designed by caregivers, aiming to enhance communication between them and create joyful memories. The cooking class will begin with 20-30 minutes an interactive nutrition-based session. The session themes will focus on healthy diet and food safety. Participants will be able to ask questions and make comments.
Study NCT05141435 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: infants receive primary non-invasive respiratory support by mean of nCPAP
Description: neonates assigned to the nCPAP group will be started on a pressure of 6 cmH2O( adjust range:6-10 cmH2O) , with FiO2 (0.21-0.40)adjusted to target SpO2 from 89% to 94%. CPAP will be provided by either variable flow or continuous flow devices, as there is no clear evidence that one type of CPAP generator would be better than any other by pure CPAP system.
Study NCT05575401 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral pharyngoplasty
Description: Two figure-of-8 sutures using 3-0 vicryl are used to approximate the anterior and posterior tonsillar pillars and reconstruct the continuous mucosal covering of the lateral pharyngeal walls.
Study NCT05575401 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tonsillectomy
Description: Extracapsular tonsillectomy
Study NCT05575401 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Description: Extracapsular tonsillectomy
Study NCT04708041 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine
Description: 9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
Study NCT05141435 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: infants receive primary non-invasive respiratory support by mean of NHFOV
Description: neonates assigned to NHFOV will be started with the following boundaries: a) Paw of 6 cmH2O (the range 6-10 cmH2O); b) frequency of 10 Hz (the range 8-12 Hz). c) Inspiratory time 50% (1:1). d) amplitude 15 cmH2O(the range 15-25 cmH2O) NHFOV will only be provided with piston/ membrane oscillators able to provide an active expiratory phase (that is, Acutronic FABIAN-III, SLE 5000, Loweinstein Med LEONI+, Sensormedics 3100A).
Study NCT04708041 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 9vHPV vaccine
Description: 9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
Study NCT05875025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo formulated with HFA-152a propellant via pMDI
Description: 5 inhalations BID (morning and evening) for 8 consecutive days, starting from the morning of Day 1 until the morning of Day 8
Study NCT05875025 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo formulated with HFA-134a propellant via pMDI
Description: 5 inhalations BID (morning and evening) for 8 consecutive days, starting from the morning of Day 1 until the morning of Day 8
Study NCT05706220 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Eye tracking
Description: Eye tracker will be used to evaluate eye movements
Study NCT05693610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable OSP
Description: The portable open-source speech processing platform (OSP) is accessed on a browser via a wireless fidelity (WiFi)-enabled portable communication device that carries out all the signal processing. The processed sounds are transmitted to the ears via earpieces known as behind-the-ear receivers in the canal (same as those available with commercial hearing aids). The amount of amplification with the portable OSP will be customized for each listener based on a validated prescription.
Study NCT05693610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cloud-based OSP
Description: The cloud-based open-source speech processing platform (OSP) is hosted on a web-server which includes the software for all the signal processing. The processed sounds are transmitted to the ears via calibrated headphones. The amount of amplification with the cloud-based OSP will be customized for each listener based on a validated prescription.
Study NCT04793958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX849
Description: 28 Day Cycle
Study NCT04793958 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 28 Day Cycle
Study NCT04793958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6 Regimen
Description: * Fluorouracil~* Oxaliplatin~* Folinic acid
Study NCT04793958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI Regimen
Description: * Fluorouracil~* Irinotecan~* Folinic acid
Study NCT05426564 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra System
Description: Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Study NCT06262061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: 20mg oral propranolol BID x 14 days
Study NCT06262061 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill orally BID x 14 days
Study NCT06478056 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: pancreatectomy
Description: patients operated on for pancreatic adenocarcinoma in the digestive surgery department of Rouen University Hospital
Study NCT05021757 — intervention group
Intervention type: DEVICE
Intervention: Shockwave C2 Coronary IVL
Description: PCI procedure using a Shockwave C2 coronary IVL catheter
Study NCT05930002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin Tablets
Description: oral tablets (0.2 mg/kg/day) single dose on an empty stomach for three successive days.
Study NCT05930002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.5 MG
Description: 0.5mg tablets (3times/day after meal for 3 days then twice daily for 4 days)
Study NCT05930002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standared managment
Description: (Vitamin C 500mg tablet twice daily, Vitamin D3 2000-4000 IU/day, Zinc 75mg tablet once daily for two weeks
Study NCT05706220 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Microperimetry
Description: Perimetric examination with Expert Exam strategy Microperimetry be used for fixation test
Study NCT05706220 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography (OCT)
Description: Macular Cube 512x128 or 200x200 scan. OCT will be used to analysis of retinal nerve fiber layer, ganglion cell complex and ganglion-cell/inner plexiform layer
Study NCT05706220 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Visual processing speed test
Description: Visual processing speed test will be used for assessing subject visual stimulus search and reach times.~Thirty-two different everyday visual stimuli divided in four complexity groups that were presented along 8 radial visual field positions at three different eccentricities.
Study NCT05627674 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care incorporates guideline awareness and brief advice.
Study NCT05627674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RiskProfile-Clin
Description: RiskProfile-Clin incorporates standard brief advice and guideline awareness plus specific patient risk feedback using clinical factors.
Study NCT05627674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RiskProfile-Gen
Description: RiskProfile-Gen incorporates standard brief advice and guideline awareness plus specific patient risk feedback using clinical factors and genetic factors.
Study NCT06033807 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: QuantiFERON-TB Gold (QFT) test
Description: Participants will be tested by QuantiFERON-TB Gold (QFT) test to see if they have ever infected by MTB. Those with positive results will proceed to sputum Xpert MTB/RIF, physical examination and chest CT scan, as well as sputum culture if necessary to distinguish latent TB infection (LTBI) from ATB. X-ray scan is conditional on age above 15 years with a positive QuantiFERON-TB Gold (QFT) test result.
Study NCT04261413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RS-0139
Description: RS-0139 will be administered for the indication of solid tumors.
Study NCT05407870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate Injection
Description: Proofol and etomidate are drugs used for sedation and have the same white color.~Gastric endoscopic submucosal dissection is performed using propofol in the control group and etomidate in the experimental group.~Efficacy and safety of sedatives were confirmed using propofol and etomidate.
Study NCT05407870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Injection
Description: Proofol and etomidate are drugs used for sedation and have the same white color.~Gastric endoscopic submucosal dissection is performed using propofol in the control group and etomidate in the experimental group.~Efficacy and safety of sedatives were confirmed using propofol and etomidate.